Dr. Lamm's bibliography includes more than 270 publications. Below is a partial list that represents Dr. Lamm's areas of interest and expertise.

Selected Publications

  1. Lamm DL, Harris SC and Gittes RF: Bacillus Calmette-Guerin and Dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Invest Urology 14:369, 1977.
  2. Lamm DL, Reichert DF, Radwin HM and Thor DE: Bacillus Calmette-Guerin immunotherapy of the cancer-contaminated wound. J Surg Res 27(1):14-22, 1979.
  3. Lamm DL, Yee GN, Reichert DF and Radwin HM: Levamisole immunotherapy of experimental transitional cell carcinoma. Invest Urol 16(4):286-288, 1979.
  4. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD and Radwin HM: BCG immunotherapy of superficial bladder cancer. J Urol 124(1):38-40, 1980.
  5. Lamm DL, Reyna JA and Reichert DF: Keyhole-Limpet Hemocyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol Res 9(5):227-230, 1981.
  6. Lamm DL, Thor DE, Winters WD, Stogdill VD and Radwin HM: BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 48(1):82-88, 1981.
  7. Lamm DL, Thor DE, Stogdill VD and Radwin HM: Bladder cancer immunotherapy. J Urol 128(5):931-935, 1982.
  8. Lamm DL, Reichert FD, Harris SC and Lucio RM: Immunotherapy of murine transitional cell carcinoma. J Urol 128(5):1104-1108, 1982.
  9. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134(1):40-47, 1985.
  10. Lamm DL: Bacillus Calmette-Guerin immunotherapy. J Urol 138(2): 391-392, 1987.
  11. Lamm DL: BCG in carcinoma in situ and superficial bladder tumors. EORTC Genitourinary Group Monograph 5: Progress and Controversies in Oncological Urology II. Prog Clin Biol Res 269:497-507, 1988.
  12. Lamm DL, Crissman J, Blumenstein B, et al: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. Prog Clin Biol Res 310(11):263-270, 1989.
  13. Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D and Sarosdy MF: A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guerin for superficial bladder cancer. J Urol 144(1):65-67, 1990.
  14. Lamm DL, Riggs DR, DeHaven JI and Bryner RW: Immunotherapy of murine bladder cancer by irradiated tumor vaccine. J Urol 145(1):195-198, 1991.
  15. Lamm DL, DeHaven JI, Shriver J and Sarosdy MF: Prospective randomized comparison of intravesical with percutaneous Bacillus Calmette-Guerin versus intravesical Bacillus Calmette-Guerin in superficial bladder cancer. J Urol 145(4):738-740, 1991.
  16. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan, J, Sarosdy, MF, Crissman, JD and Coltman, CA: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. New Engl J Med 325(17):1205-1209, 1991
  17. Lamm DL, DeHaven JI, Riggs DR and Ebert RF: Immunotherapy of murine bladder cancer with Keyhole Limpet Hemocyanin (KLH). J Urol 149(3):648-652, 1993.
  18. Lamm DL, DeHaven JI, Riggs DR, Delgra A, and Burrell R: Immunotherapy of Murine Transitional Cell Carcinoma with Immucothel, a Modification of Keyhole Limpet Hemocyanin (KLH). Urol Res 21: 21-33, 1993.
  19. Lamm DL, Riggs DR, Shriver JS, VanGilder PF, Rach JF and DeHaven JI: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151(1):21-26, 1994.
  20. Lamm DL, Riggs DR, Traynelis CT and Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444-50, 1995.
  21. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, and Grossman, HB: Randomized Intergroup Comparison of Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Chemotherapy PrRophylaxis in Superficial Transitional Cell Carcinoma of the Bladder. A Southwest Oncology Group Study. Urol Oncol 1:119-126, 1995.
  22. Riggs DR, DeHaven JI and Lamm DL: Allium sativum (garlic) Treatment for Murine Transitional Cell Carcinoma. Cancer 79(10):1987-1994, 1997.
  23. Lamm DL: Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin 48(5): 263-268, 1998
  24. Lamm DL, Riggs DR, Donley MS, White J, Yeater R, and Bryner RW: Bacillus Calmette-Guerin Immunotherapy Significantly Prolongs Survival of Animals with Prostate Cancer. The Prostate Journal 1(4): 190-194, 1999.
  25. Lamm DL and Riggs DR: The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27(1): 157-162, 2000.
  26. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, and Crawford ED: Maintenance bacillus Calmette-Guerin immunoterapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4): 1124-1129, 2000.
  27. Lamm DL: Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 31 Suppl 3:S86-90, 2000.
  28. Hogan TF, Lamm DL, Ducatman AM. Smoking and renal cell carcinoma. W V Med J. 97(1):32-5, 2001.
  29. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA: Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev. 25(1):62-75, 2001.
  30. Kamat AM, Lamm DL: Immunotherapy for bladder cancer. Curr Urol Rep. 2(1):62-9, 2001.
  31. Kamat AM, Lamm DL: Chemoprevention of bladder cancer. Urol Clin North Am. 29(1):157-68, 2002.
  32. Lamm DL: Superficial bladder cancer. Curr Treat Options Oncol. 3(5):403-11, 2002.
  33. Sylvester RJ, van der MEIJDEN AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168(5):1964-70, 2002.
  34. Simon SD, Ferrigni RG, Novicki DE, Lamm DL, Swanson SS, Andrews PE: Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumors. J Urol. 169(6):2059-62, 2003.
  35. Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology. 63(3):457-60, 2004.
  36. Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, Andrews PE: Complications of laparoscopic nephrectomy: the Mayo clinic experience. J Urol. 171:1447-50, 2004.
  37. Schenkman E, Lamm DL. Superficial bladder cancer therapy. ScientificWorldJournal. 1 (Suppl):387-99, 2004.